Wegovy

is a revolutionary weight loss medication launched by Novo Nordisk, with the active ingredient being Semaglutide, a GLP-1 receptor agonist. By mimicking intestinal hormones, Wegovy effectively suppresses appetite, delays gastric emptying, and promotes insulin secretion, helping to control blood sugar and body weight.

What is the mechanism of action of Wegovy?

GLP-1 Receptor Agonist: Semaglutide mimics the intestinal hormone GLP-1, activating related receptors to regulate blood sugar and appetite.

• Promotes Insulin Secretion: When blood sugar levels rise, it stimulates the pancreatic beta cells to release insulin, helping to lower blood sugar levels.
• Inhibits Glucagon: Reduces the release of glucose from the liver, preventing further increases in blood sugar.
• Delays Gastric Emptying: Slows the rate at which food moves from the stomach to the small intestine, prolonging feelings of fullness and stabilizing blood sugar fluctuations.
• Suppresses Appetite and Aids Weight Loss: Acts on the brain's appetite center to reduce food intake, thereby promoting weight management.

Who is suitable for using Wegovy?

Wegovy is suitable for the following two groups of adults:

• Adults with Obesity: Adults with a BMI ≥ 30 kg/m², used for chronic weight management.
• Overweight Individuals with Associated Diseases: Individuals with a BMI ≥ 27 kg/m² who have at least one weight-related condition, such as hypertension, type 2 diabetes, high cholesterol, or cardiovascular disease.

Not recommended for users:

• Thyroid-Related Conditions: Individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2).
• Allergy History: Those who are allergic to Semaglutide or its components.
• Pregnant or Breastfeeding: Women who are pregnant, planning to become pregnant, or breastfeeding (as it may affect fetal development).
• Severe Gastrointestinal Issues: Individuals with severe gastrointestinal diseases, a history of pancreatitis, or gallbladder disease.
• Other High-Risk Groups: Those with a history of diabetic ketoacidosis, severe renal impairment, or heart failure require physician evaluation.

Differences Between Wegovy and Other Weight Loss Medications

Most weight loss medications on the market target only the GLP-1 receptors. This breakthrough in mechanism allows it to demonstrate more significant weight loss effects in clinical trials.

Research indicates that some users can lose up to 20% of their body weight, outperforming single-receptor medications. However, the actual effectiveness still depends on individual body composition and lifestyle.

Dosage and Administration

Wegovy is administered as a subcutaneous injection once a week, and can be injected into the abdomen, thigh, or upper arm, without needing to sync with meal times. The recommended dosage adjustment is as follows:

• Weeks 1-4: 0.25 mg, once a week.
• Weeks 5-8: 0.5 mg, once a week.
• Weeks 9-12: 1 mg, once a week.
• Weeks 13-16: 1.7 mg, once a week.
• Week 17 onwards: Maintenance dose of 2.4 mg, once a week (can be adjusted based on tolerance).

Please Note: Dosage adjustments must be evaluated and directed by a physician. Do not increase the dosage or change the administration method on your own.

Wegovy Side Effects:

During the use of Wegovy, some individuals may experience gastrointestinal discomfort. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These reactions are typically mild to moderate and tend to gradually alleviate with continued use.

However, in rare cases, more severe side effects may occur, such as pancreatitis, gallbladder issues, renal dysfunction, and even a potential risk of thyroid tumors. It is recommended to closely monitor changes in the body during use. If severe abdominal pain, persistent vomiting, or other abnormal symptoms occur, discontinue the medication immediately and seek medical assistance.

Precautions Before Using Wegovy:

1. Long-term Medical Monitoring Required: Wegovy is suitable for long-term weight management, but like all prescription medications, long-term use may still pose risks. Users should schedule regular follow-up appointments for the physician to assess effectiveness and overall health status and address any potential issues promptly.
2. Avoid Concomitant Use with Other GLP-1 Agonists: Do not combine Wegovy with other GLP-1 receptor agonists to prevent drug interactions. Before use, proactively inform your physician about any prescription medications, over-the-counter drugs, or dietary supplements you are currently taking to enable the physician to make the most appropriate judgment.

*The information in this text is for reference only. Actual dosage and timing of medication should be directed by a doctor and used correctly according to the product manual.

Handling and Storage Instructions:Unused Pen:

• Store unused pens in a refrigerator at 2°C to 8°C.
• If kept in the refrigerator, unused pens can be used until the expiration date printed on the label.
• If accidentally frozen, the pen must be discarded and should not be used. Please dispose of it properly.

Used Pen:

• After injection, store used pens at room temperature below 30°C.
• Keep away from high temperatures.
• Store pens and needles out of sight and reach of children.
• If the full weekly dosage has been completed four times, a new pen should be replaced promptly.

Registration number

0.5mg: 1C 15054/66 (NC)

‍

‍